Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history

被引:47
作者
Tonin, PN
Mes-Masson, AM
Narod, SA
Ghadirian, P
Provencher, D
机构
[1] Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada
[2] McGill Univ, Dept Med, Montreal, PQ, Canada
[3] McGill Univ, Dept Human Genet, Montreal, PQ, Canada
[4] CHUM, Inst Canc Montreal, Montreal, PQ, Canada
[5] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
[6] Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5S 1B2, Canada
[7] Univ Toronto, Toronto, ON, Canada
[8] CHUM, Unite Rech Epidemiol, Montreal, PQ, Canada
[9] Univ Montreal, Fac Med, Dept Nutr, Montreal, PQ H3C 3J7, Canada
[10] Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J7, Canada
关键词
BRCA1; BRCA2; breast cancer; ovarian cancer;
D O I
10.1034/j.1399-0004.1999.550504.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The breast cancer susceptibility genes, BRCA1 and BRCA2, differ in their contribution to ovarian cancer. Recently, founder mutations in each of these genes were identified in Canadian breast cancer and breast-ovarian cancer families of French ancestry. We have examined the prevalence of the founder mutations in a series of 113 French Canadian women with ovarian cancer unselected for family history. Germline mutations were found in eight of 99 invasive carcinomas and in none of the 14 tumors of borderline malignancy. Five cases carried the BRCA1 C4446T mutation and two cases carried the BRCA2, 8765delAG mutation which are the most common mutations that have been described in French Canadian breast cancer and breast-ovarian cancer families. All of these cases reported a family history of at least one first-degree relative with breast cancer, diagnosed below age 60 years, or with ovarian cancer. The identification of founder BRCA1 and BRCA2 mutations in ovarian cancer cases unselected for family history can facilitate earlier detection when the expected yield of a comprehensive screen may be low.
引用
收藏
页码:318 / 324
页数:7
相关论文
共 43 条
[11]  
LevyLahad E, 1997, AM J HUM GENET, V60, P1059
[12]  
Liede A, 1998, AM J MED GENET, V75, P55, DOI 10.1002/(SICI)1096-8628(19980106)75:1<55::AID-AJMG12>3.0.CO
[13]  
2-R
[14]   Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [J].
Liu, B ;
Parsons, R ;
Papadopoulos, N ;
Nicolaides, NC ;
Lynch, HT ;
Watson, P ;
Jass, JR ;
Dunlop, M ;
Wyllie, A ;
Peltomaki, P ;
delaChapelle, A ;
Hamilton, SR ;
Vogelstein, B ;
Kinzler, KW .
NATURE MEDICINE, 1996, 2 (02) :169-174
[15]  
LYNCH HT, 1993, CANCER-AM CANCER SOC, V71, P573
[16]   FAMILIAL OVARIAN-CARCINOMA - CLINICAL NUANCES [J].
LYNCH, HT ;
BEWTRA, C ;
LYNCH, JF .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (06) :1073-1076
[17]   HEREDITARY NONPOLYPOSIS COLORECTAL-CANCER - THE SYNDROME, THE GENES, AND HISTORICAL PERSPECTIVES [J].
MARRA, G ;
BOLAND, CR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (15) :1114-1125
[18]   MUTATION ANALYSIS OF THE BRCA1 GENE IN 76 JAPANESE OVARIAN-CANCER PATIENTS - 4 GERMLINE MUTATIONS, BUT NO EVIDENCE OF SOMATIC MUTATION [J].
MATSUSHIMA, M ;
KOBAYASHI, K ;
EMI, M ;
SAITO, H ;
SAITO, J ;
SUZUMORI, K ;
NAKAMURA, Y .
HUMAN MOLECULAR GENETICS, 1995, 4 (10) :1953-1956
[19]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[20]   HISTOLOGY OF BRCA1-ASSOCIATED OVARIAN-TUMORS [J].
NAROD, S ;
TONIN, P ;
LYNCH, H ;
WATSON, P ;
FEUNTEUN, J ;
LENOIR, G .
LANCET, 1994, 343 (8891) :236-236